Loading page
Loading page
Loading substance route
Compound purity and quality vary significantly across suppliers. Subjective effects show substantial inter-batch variability which may relate to tolerance, individual factors, and synthesis variations in isomer ratios.
Effects vary widely by individual, dose, and context.
The physical effects of ethylphenidate can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of ethylphenidate can be broken down into several components which progressively intensify proportional to dosage. The general head space of ethylphenidate is described by many as one of extreme mental stimulation, increased focus, and powerful euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate dosages, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
Ethylphenidate is considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. Compulsive redosing is commonly reported. Cravings may occur if use is suddenly stopped.
Withdrawal effects have been reported upon cessation of chronic use, though the specific nature and severity of physical dependence is not well documented due to the substance's limited research history.
The exact toxic dosage is unknown due to ethylphenidate's very limited history of human usage and lack of scientific study.
Ethylphenidate crystals are particularly abrasive and caustic to mucous membranes; repeated insufflation can deteriorate nasal tissue and potentially damage the nasal septum, leading harm reduction sources to recommend against this route of administration.
Inhalation of ethylphenidate irritates lung tissue, resulting in phlegm production and an irritated cough.
Prolonged use causes vasoconstriction and cardiovascular strain including increased heart rate and blood pressure; occasional use at moderate doses carries less risk, though chest pain has been reported as a side effect.
Abuse at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Based on research into related stimulants, approximately 5–15% of users who develop stimulant psychosis may not fully recover, though antipsychotic medications can effectively resolve acute symptoms.
Ethylphenidate emerged on the recreational drug market around 2010-2011 and gained increasing popularity over the subsequent years. It became primarily distributed as a research chemical through online vendors, exploiting its grey-area legal status in various jurisdictions during this period. The…
Not controlled under international drug treaties
Australian state and federal legislation contains provisions covering analogues of controlled drugs. Ethylphenidate falls under these provisions as an analogue of methylphenidate.
Listed on the Controlled Drugs and Substances Act in Schedule III as of May 5, 2017. Previously unscheduled with no analog law covering it.
Controlled under Anlage II of the Betäubungsmittelgesetz (Narcotics Act) as of July 17, 2013. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license is prohibited.
Listed in Lijst I of the Opiumwet (Opium Act) as of April 27, 2018.
Listed in Appendix 1 of Swedish drug control regulations as of December 15, 2012, making it illegal for most purposes.
Initially placed under emergency control as a Temporary Class Drug in April 2015 along with other phenidates, restricting sale and manufacture. Subsequently classified as a Class B drug on May 31, 2017, making possession, production, and supply illegal.
Prohibited since January 1, 2012 under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act).
Controlled substance as of February 1, 2013.
Controlled under the Misuse of Drugs (Jersey) Law 1978.
Not specifically listed as controlled under the Forskrift om narkotika (narcotics regulation). Despite structural similarity to methylphenidate, Norwegian law does not automatically control ethylphenidate as an analogue.
Specifically named as a controlled substance under Verzeichnis D of Swiss drug regulations.
Not explicitly scheduled at the federal level. However, as a structural analogue of methylphenidate (Schedule II), it could potentially be prosecuted under the Federal Analogue Act if sold for human consumption or possessed with intent to ingest. Specifically controlled in Utah along with its analogues, homologs, and synthetic equivalents.
